End-Stage Renal Disease (ESRD) Market Growth Opportunities, Clinical Developmental Activities, Emerging Therapies, Epidemiology Forecast in the 7MM | Leading Companies – Pfizer, Akebia Therapeutics
DelveInsight has launched a new report on “End-Stage Renal Disease (ESRD) Market Insights, Epidemiology, and Market Forecast-2032”.
DelveInsight’s “End-Stage Renal Disease (ESRD) Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the End-Stage Renal Disease (ESRD), historical and forecasted epidemiology as well as the End-Stage Renal Disease (ESRD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the End-Stage Renal Disease (ESRD) Market Report:
- End-stage renal disease is a rapidly increasing global health and health care burden
- The prevalence of End-Stage Renal Disease in the 7MM was estimated to be 115 Million cases in 2021
- In the United States, the prevalence of End-Stage Renal Disease is expected to rise in from 20% – to 35% for adults in the age group 45-64 years
- People in the age group 65-74 years are more prone to the End-Stage Renal Disease and the survival rate is also low at that stage
Request a sample for the Report: https://www.delveinsight.com/sample-request/end-stage-renal-disease-esrd-market
Key benefits of the report:
- End-Stage Renal Disease (ESRD) market report covers a descriptive overview and comprehensive insight of the End-Stage Renal Disease (ESRD) Epidemiology and End-Stage Renal Disease (ESRD) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The End-Stage Renal Disease (ESRD) market report provides insights on the current and emerging therapies.
- End-Stage Renal Disease (ESRD) market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The End-Stage Renal Disease (ESRD) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the End-Stage Renal Disease (ESRD) market.
Got queries? Click here to know more about the End-Stage Renal Disease (ESRD) Market Landscape
End-Stage Renal Disease (ESRD) Overview
End-stage renal disease (ESRD) also known as end-stage renal failure is the final, permanent stage of chronic kidney disease, where kidney function has declined to the point that the kidneys can no longer function on their own. In this condition, kidneys are only functioning at 10–15% of their normal capacity. A patient with end-stage renal failure must receive dialysis or kidney transplantation in order to survive for more than a few weeks.
Patients may experience a wide variety of symptoms as kidney failure progresses. These include fatigue, drowsiness, decrease in urination or inability to urinate, dry skin, itchy skin, headache, weight loss, nausea, bone pain, skin and nail changes, and easy bruising. Diabetic nephropathy (DN) is one of the most common complications of diabetes and the leading cause of the end-stage renal disease (ESRD). Approximately 30–40% of diabetes mellitus patients in the world progress to ESRD, which emphasizes the effect of genetic factors on DN.
End-Stage Renal Disease (ESRD) Symptoms:
The symptoms of End-Stage Renal Disease include –
- Nausea and vomiting
- Loss of appetite
- Body Fatigue and weakness
- Change in the Urine Cycle
- Pain in chest
- Shortness in breathing
End-Stage Renal Disease (ESRD) Market
The dynamics of the End-Stage Renal Disease (ESRD) market are anticipated to change in the coming years due to the expected launch of emerging therapies such as AZD1722, ISIS 416858, eravacycline, and others during the forecasted period 2019-2032.
Learn more by requesting for sample @End Stage Renal Disease (ESRD) Market Landscape
End-Stage Renal Disease (ESRD) Pipeline Therapies:
- eravacycline
- Rivaroxaban
- ISIS 416858
- Roxadustat
- Epoetin Alfa
- AZD1722
End-Stage Renal Disease (ESRD) Pipeline Key Companies:
- Pfizer
- Akebia Therapeutics
- Astellas Pharma
- Ionis Pharmaceuticals
- Tetraphase Pharmaceuticals
- Pinta Biotherapeutics
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. End-Stage Renal Disease (ESRD) Patient Share (%) Overview at a Glance
5. End-Stage Renal Disease (ESRD) Market Overview at a Glance
6. End-Stage Renal Disease (ESRD) Disease Background and Overview
7. End-Stage Renal Disease (ESRD) Epidemiology and Patient Population
8. Country-Specific Patient Population of End-Stage Renal Disease (ESRD)
9. End-Stage Renal Disease (ESRD) Current Treatment and Medical Practices
10. Unmet Needs
11. End-Stage Renal Disease (ESRD) Emerging Therapies
12. End-Stage Renal Disease (ESRD) Market Outlook
13. Country-Wise End-Stage Renal Disease (ESRD) Market Analysis (2018–2030)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. End-Stage Renal Disease (ESRD) Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Click here to read more about End-Stage Renal Disease (ESRD) Market Outlook 2032
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com
 Market Growth Opportunities, Clinical Developmental Activities, Emerging Therapies, Epidemiology Forecast in the 7MM | Leading Companies – Pfizer, Akebia Therapeutics){kind=link}